We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Netflix, Toyota, AbbVie, Merck and Sinopec
Read MoreHide Full Article
For Immediate Release
Chicago, IL – March 15, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Netflix, Inc. (NFLX - Free Report) , Toyota Motor Corporation (TM - Free Report) , AbbVie Inc. (ABBV - Free Report) , Merck & Co., Inc. (MRK - Free Report) and China Petroleum & Chemical Corporation .
Here are highlights from Friday’s Analyst Blog:
Top Stock Reports for Netflix, Toyota and AbbVie
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Netflix, Toyota and AbbVie. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Netflix shares have underperformed the Zacks Broadcast Radio and Television industry over the past year (+52.7% vs. +83%). The Zacks analyst believes that Netflix has been benefiting from heavy investments in the production and distribution of localized, foreign-language content.
Higher numbers of originals are expected to aid user-base growth in 2021 despite rising competition from Apple TV+, Amazon prime video, HBO Max, Disney+, Peacock, Discovery+ and TikTok. The company plans to release at least one new original film every week in 2021. User-friendly features like Downloads For You and more efficient Parental Controls are key positives.
The launch of low-priced mobile plans is also expected to expand Netflix's subscriber base in Asia Pacific. However, Netflix's leveraged balance sheet and higher streaming obligation is also a concern.
Shares of Toyota have gained +12.2% in the last six months against the Zacks Foreign Automotive industry's gain of +29.9%. The Zacks analyst believes that the firm's sharp focus on electric vehicles (EVs) and driverless cars offer ample growth visibility.
Toyota targets to achieve 40% of its global sales from EVs by 2025 and nearly 70% by 2035. Partnership with Subaru and Mazda is likely to drive Toyota's electrification plans. Collaboration with Hino, Aurora, Uber and Pony.ai also augur well. Thus, Toyota is viewed as a lucrative bet.
Toyota put up a stellar show in fiscal third quarter 2021, with earnings and sales not just beating estimates but also rising year over year. The upward revision of its fiscal 2021 view is encouraging. The company now projects 2021 operating income at ¥2,000 billion, up from the prior estimate of ¥1,300 billion.
AbbVie's shares have gained +3.2% over the past three months against the Zacks Large-Cap Pharmaceuticals industry's gain of +1.6%. The Zacks analyst believes that AbbVie's key drug, Humira, continues to see strong demand trends in the United States.
AbbVie has been successful in expanding labels of its cancer drugs, Imbruvica and Venclexta. It has an impressive late-stage pipeline with several early/mid-stage pipeline candidates that have blockbuster potential. Its two new immunology drugs, Skyrizi and Rinvoq, performed beyond expectations in 2020.
Allergan's acquisition has diversified AbbVie's revenue base into new therapeutic areas. However, sales erosion due to direct biosimilar competition to Humira in international markets is a big headwind. Also, the decline in HCV drug Mavyret's sales is a concern.
Other noteworthy reports we are featuring today include Merck and Sinopec.
5G Revolution: 3 Stocks to Make Your Move
With super high data speed, it will make current cell phones obsolete and unlock the full potential of big data, cloud computing, and artificial intelligence. In the next few years this industry is predicted to create 22 million jobs and a stunning $12.3 trillion in revenue.
Today you have an historic chance to pursue almost unimaginable gains like Microsoft, Netflix, and Apple in their early phases. Zacks has released a Special Report that reveals our . . .
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Netflix, Toyota, AbbVie, Merck and Sinopec
For Immediate Release
Chicago, IL – March 15, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Netflix, Inc. (NFLX - Free Report) , Toyota Motor Corporation (TM - Free Report) , AbbVie Inc. (ABBV - Free Report) , Merck & Co., Inc. (MRK - Free Report) and China Petroleum & Chemical Corporation .
Here are highlights from Friday’s Analyst Blog:
Top Stock Reports for Netflix, Toyota and AbbVie
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Netflix, Toyota and AbbVie. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Netflix shares have underperformed the Zacks Broadcast Radio and Television industry over the past year (+52.7% vs. +83%). The Zacks analyst believes that Netflix has been benefiting from heavy investments in the production and distribution of localized, foreign-language content.
Higher numbers of originals are expected to aid user-base growth in 2021 despite rising competition from Apple TV+, Amazon prime video, HBO Max, Disney+, Peacock, Discovery+ and TikTok. The company plans to release at least one new original film every week in 2021. User-friendly features like Downloads For You and more efficient Parental Controls are key positives.
The launch of low-priced mobile plans is also expected to expand Netflix's subscriber base in Asia Pacific. However, Netflix's leveraged balance sheet and higher streaming obligation is also a concern.
(You can read the full research report on Netflix here >>>)
Shares of Toyota have gained +12.2% in the last six months against the Zacks Foreign Automotive industry's gain of +29.9%. The Zacks analyst believes that the firm's sharp focus on electric vehicles (EVs) and driverless cars offer ample growth visibility.
Toyota targets to achieve 40% of its global sales from EVs by 2025 and nearly 70% by 2035. Partnership with Subaru and Mazda is likely to drive Toyota's electrification plans. Collaboration with Hino, Aurora, Uber and Pony.ai also augur well. Thus, Toyota is viewed as a lucrative bet.
Toyota put up a stellar show in fiscal third quarter 2021, with earnings and sales not just beating estimates but also rising year over year. The upward revision of its fiscal 2021 view is encouraging. The company now projects 2021 operating income at ¥2,000 billion, up from the prior estimate of ¥1,300 billion.
(You can read the full research report on Toyota Motor here >>>)
AbbVie's shares have gained +3.2% over the past three months against the Zacks Large-Cap Pharmaceuticals industry's gain of +1.6%. The Zacks analyst believes that AbbVie's key drug, Humira, continues to see strong demand trends in the United States.
AbbVie has been successful in expanding labels of its cancer drugs, Imbruvica and Venclexta. It has an impressive late-stage pipeline with several early/mid-stage pipeline candidates that have blockbuster potential. Its two new immunology drugs, Skyrizi and Rinvoq, performed beyond expectations in 2020.
Allergan's acquisition has diversified AbbVie's revenue base into new therapeutic areas. However, sales erosion due to direct biosimilar competition to Humira in international markets is a big headwind. Also, the decline in HCV drug Mavyret's sales is a concern.
(You can read the full research report on AbbVie here >>>)
Other noteworthy reports we are featuring today include Merck and Sinopec.
5G Revolution: 3 Stocks to Make Your Move
With super high data speed, it will make current cell phones obsolete and unlock the full potential of big data, cloud computing, and artificial intelligence. In the next few years this industry is predicted to create 22 million jobs and a stunning $12.3 trillion in revenue.
Today you have an historic chance to pursue almost unimaginable gains like Microsoft, Netflix, and Apple in their early phases. Zacks has released a Special Report that reveals our . . .
Download now. Today the report is FREE >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.